These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody. Vallera DA, Brechbiel MW, Burns LJ, Panoskaltsis-Mortari A, Dusenbery KE, Clohisy DR, Vitetta ES. Clin Cancer Res; 2005 Nov 01; 11(21):7920-8. PubMed ID: 16278417 [Abstract] [Full Text] [Related]
26. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y. Price EW, Edwards KJ, Carnazza KE, Carlin SD, Zeglis BM, Adam MJ, Orvig C, Lewis JS. Nucl Med Biol; 2016 Sep 01; 43(9):566-576. PubMed ID: 27419360 [Abstract] [Full Text] [Related]
28. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems. Williams LE, Lewis MR, Bebb GG, Clarke KG, Odom-Maryon TL, Shively JE, Raubitschek AA. Bioconjug Chem; 1998 Jan 01; 9(1):87-93. PubMed ID: 9460550 [Abstract] [Full Text] [Related]
29. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands. Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR. Nucl Med Biol; 2010 Oct 01; 37(7):741-50. PubMed ID: 20870149 [Abstract] [Full Text] [Related]
30. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G, Guiducci G, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maeke HR. Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375 [Abstract] [Full Text] [Related]
31. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. J Nucl Med; 2005 Nov 01; 46(11):1898-906. PubMed ID: 16269605 [Abstract] [Full Text] [Related]
32. Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice. Sharkey RM, Motta-Hennessy C, Gansow OA, Brechbiel MW, Fand I, Griffiths GL, Jones AL, Goldenberg DM. Int J Cancer; 1990 Jul 15; 46(1):79-85. PubMed ID: 2114375 [Abstract] [Full Text] [Related]
33. The effect of chelating agents on the distribution of monoclonal antibodies in mice. Ward MC, Roberts KR, Westwood JH, Coombes RC, McCready VR. J Nucl Med; 1986 Nov 15; 27(11):1746-50. PubMed ID: 3464701 [Abstract] [Full Text] [Related]
34. In vitro and in vivo comparison of DTPA- and DOTA-conjugated antiferritin monoclonal antibody for imaging and therapy of pancreatic cancer. Sabbah EN, Kadouche J, Ellison D, Finucane C, Decaudin D, Mather SJ. Nucl Med Biol; 2007 Apr 15; 34(3):293-304. PubMed ID: 17383579 [Abstract] [Full Text] [Related]
35. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, Liu Z, Brechbiel MW, Hanai N, Nice EC, Catimel B, Burgess AW, Welt S, Ritter G, Old LJ, Scott AM. Cancer Res; 2001 Jun 01; 61(11):4474-82. PubMed ID: 11389078 [Abstract] [Full Text] [Related]
36. Biodistribution study of 188Re-labeled trisuccin-HuCC49 and trisuccin-HuCC49deltaCh2 conjugates in athymic nude mice bearing intraperitoneal colon cancer xenografts. Safavy A, Khazaeli MB, Safavy K, Mayo MS, Buchsbaum DJ. Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):2994s-3000s. PubMed ID: 10541333 [Abstract] [Full Text] [Related]
37. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH. Nucl Med Biol; 2011 Nov 01; 38(8):1119-27. PubMed ID: 21741258 [Abstract] [Full Text] [Related]
38. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. Chong HS, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW. Nucl Med Biol; 2006 May 01; 33(4):459-67. PubMed ID: 16720237 [Abstract] [Full Text] [Related]
39. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, Waldmann TA. Cancer Res; 1989 May 15; 49(10):2639-44. PubMed ID: 2785435 [Abstract] [Full Text] [Related]
40. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. Kosmas C, Maraveyas A, Gooden CS, Snook D, Epenetos AA. J Nucl Med; 1995 May 15; 36(5):746-53. PubMed ID: 7738643 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]